|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Okusaka T, Funakoshi A, Furuse J, Boku N,
Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for
metastatic pancreatic cancer. Cancer Chemother Pharmacol.
61:615–621. 2008. View Article : Google Scholar
|
|
3
|
Morizane C, Okusaka T, Furuse J, Ishii H,
Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T and Suzuki E: A phase
II study of S-1 in gemcitabine-refractory metastatic pancreatic
cancer. Cancer Chemother Pharmacol. 63:313–319. 2009. View Article : Google Scholar
|
|
4
|
Sudo K, Yamaguchi T, Nakamura K, Denda T,
Hara T, Ishihara T and Yokosuka O: Phase II study of S-1 in
patients with gemcitabine-resistant advanced pancreatic cancer.
Cancer Chemother Pharmacol. 67:249–254. 2011. View Article : Google Scholar
|
|
5
|
Sasaki T, Isayama H, Yashima Y, Yagioka H,
Kogure H, Arizumi T, Togawa O, Matsubara S, Ito Y, Nakai Y, et al:
S-1 monotherapy in patients with advanced biliary tract cancer.
Oncology. 77:71–74. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsuji W, Ishiguro H, Tanaka S, Takeuchi M,
Ueno T and Toi M: Orally administered S-1 suppresses circulating
endothelial cell counts in metastatic breast cancer patients. Int J
Clin Oncol. 19:452–459. 2014. View Article : Google Scholar
|
|
7
|
Saek T, Takashima S, Sano M, Horikoshi N,
Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, et al: A
phase II study of S-1 in patients with metastatic breast cancer - a
Japanese trial by the S-1 Cooperative Study Group, Breast Cancer
Working Group. Breast Cancer. 11:194–202. 2004. View Article : Google Scholar
|
|
8
|
Lee SJ, Lee J, Park SH, Park JO, Park YS,
Kang WK, Lee J, Yim DS and Lim HY: Phase 1 trial of S-1 in
combination with sorafenib for patients with advanced
hepatocellular carcinoma. Invest New Drugs. 30:1540–1547. 2012.
View Article : Google Scholar
|
|
9
|
Furuse J, Okusaka T, Kaneko S, Kudo M,
Nakachi K, Ueno H, Yamashita T and Ueshima K: Phase I/II study of
the pharma-cokinetics, safety and efficacy of S-1 in patients with
advanced hepatocellular carcinoma. Cancer Sci. 101:2606–2611. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pectasides D, Karavasilis V, Papaxoinis G,
Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas
E, Basdanis G, et al: Randomized phase III clinical trial comparing
the combination of capecitabine and oxaliplatin (CAPOX) with the
combination of 5-fluorouracil, leucovorin and oxaliplatin (modified
FOLFOX6) as adjuvant therapy in patients with operated high-risk
stage II or stage III colorectal cancer. BMC Cancer. 15:3842015.
View Article : Google Scholar
|
|
11
|
Argilés G, Saunders MP, Rivera F, Sobrero
A, Benson A III, Guillén Ponce C, Cascinu S, Van Cutsem E,
Macpherson IR, Strumberg D, et al: Regorafenib plus modified
FOLFOX6 as first-line treatment of metastatic colorectal cancer: A
phase II trial. Eur J Cancer. 51:942–949. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Álvarez P, Marchal JA, Boulaiz H, Carrillo
E, Vélez C, Rodríguez-Serrano F, Melguizo C, Prados J, Madeddu R
and Aranega A: 5-Fluorouracil derivatives: A patent review. Expert
Opin Ther Pat. 22:107–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maeda T, Hobbs RM and Pandolfi PP: The
transcription factor Pokemon: A new key player in cancer
pathogenesis. Cancer Res. 65:8575–8578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davies JM, Hawe N, Kabarowski J, Huang QH,
Zhu J, Brand NJ, Leprince D, Dhordain P, Cook M, Morriss-Kay G, et
al: Novel BTB/POZ domain zinc-finger protein, LRF, is a potential
target of the LAZ-3/BCL-6 oncogene. Oncogene. 18:365–375. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin CC, Zhou JP, Liu YP, Liu JJ, Yang XN,
Jazag A, Zhang ZP, Guleng B and Ren JL: The silencing of Pokemon
attenuates the proliferation of hepatocellular carcinoma cells in
vitro and in vivo by inhibiting the PI3K/Akt pathway. PLoS One.
7:e519162012. View Article : Google Scholar
|
|
17
|
Zhao Z, Wang J, Wang S, Chang H, Zhang T
and Qu J: LncRNA CCAT2 promotes tumorigenesis by over-expressed
Pokemon in non-small cell lung cancer. Biomed Pharmacother.
87:692–697. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aggarwal H, Aggarwal A and Agrawal DK:
Corrigendum to ‘Epidermal growth factor increases LRF/Pokemon
expression in human prostate cancer cells’ [Exp. Mol. Pathol. 91
(2011) 496-501]. Exp Mol Pathol. 100:3612016. View Article : Google Scholar
|
|
19
|
Kong J, Liu X, Li X, Wu J, Wu N, Chen J
and Fang F: Pokemon promotes the invasiveness of hepatocellular
carcinoma by enhancing MEF2D transcription. Hepatol Int.
10:493–500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sartini D, Lo Muzio L, Morganti S, Pozzi
V, Di Ruscio G, Rocchetti R, Rubini C, Santarelli A and Emanuelli
M: Pokemon proto-oncogene in oral cancer: Potential role in the
early phase of tumorigenesis. Oral Dis. 21:462–469. 2015.
View Article : Google Scholar
|
|
21
|
He S, Liu F, Xie Z, Zu X, Xu W and Jiang
Y: P-Glycoprotein/MDR1 regulates pokemon gene transcription through
p53 expression in human breast cancer cells. Int J Mol Sci.
11:3309–051. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao GT, Yang LJ, Li XX, Cui HL and Guo R:
Expression of the proto-oncogene Pokemon in colorectal cancer -
inhibitory effects of an siRNA. Asian Pac J Cancer Prev.
14:4999–5005. 2013. View Article : Google Scholar
|
|
23
|
Zhao Y, Yao YH, Li L, An WF, Chen HZ, Sun
LP, Kang HX, Wang S and Hu XR: Pokemon enhances proliferation, cell
cycle progression and anti-apoptosis activity of colorectal cancer
independently of p14ARF-MDM2-p53 pathway. Med Oncol. 31:2882014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Reyniès A, Assié G, Rickman DS, Tissier
F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E and
Bertherat J: Gene expression profiling reveals a new classification
of adreno-cortical tumors and identifies molecular predictors of
malignancy and survival. J Clin Oncol. 27:1108–1115. 2009.
View Article : Google Scholar
|
|
25
|
Desoize B and Jardillier J: Multicellular
resistance: A paradigm for clinical resistance? Crit Rev Oncol
Hematol. 36:193–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Green SK, Francia G, Isidoro C and Kerbel
RS: Antiadhesive antibodies targeting E-cadherin sensitize
multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer
Ther. 3:149–159. 2004.PubMed/NCBI
|
|
27
|
Zheng C, Zhou Q, Wu F, Peng Q, Tang A,
Liang H and Zeng Y: Semaphorin3F down-regulates the expression of
integrin alpha(v) beta3 and sensitizes multicellular tumor
spheroids to chemotherapy via the neuropilin-2 receptor in vitro.
Chemotherapy. 55:344–352. 2009. View Article : Google Scholar
|
|
28
|
Butler WR and Guthertz LS: Mycolic acid
analysis by high-performance liquid chromatography for
identification of Mycobacterium species. Clin Microbiol Rev.
14:704–726. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan BR, Thomas F, Myerson RJ, Zehnbauer B,
Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman
JW, et al: Thymidylate synthase genotype-directed neoadjuvant
chemoradiation for patients with rectal adenocarcinoma. J Clin
Oncol. 29:875–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Temraz S, Mukherji D, Alameddine R and
Shamseddine A: Methods of overcoming treatment resistance in
colorectal cancer. Crit Rev Oncol Hematol. 89:217–230. 2014.
View Article : Google Scholar
|
|
31
|
Sargent D, Sobrero A, Grothey A, O’Connell
MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C,
et al: Evidence for cure by adjuvant therapy in colon cancer:
Observations based on individual patient data from 20,898 patients
on 18 randomized trials. J Clin Oncol. 27:872–877. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluo-rouracil alone as first-line treatment for metastatic
colorectal cancer: A multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Giacchetti S, Perpoint B, Zidani R, Le
Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y,
Coudert B, et al: Phase III multicenter randomized trial of
oxaliplatin added to chronomodulated fluorouracil-leucovorin as
first-line treatment of metastatic colorectal cancer. J Clin Oncol.
18:136–147. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gozzetti A, Davis EM, Espinosa R III,
Fernald AA, Anastasi J and Le Beau MM: Identification of novel
cryptic translocations involving IGH in B-cell non-Hodgkin’s
lymphomas. Cancer Res. 62:5523–5527. 2002.PubMed/NCBI
|
|
35
|
Astier AL, Xu R, Svoboda M, Hinds E, Munoz
O, de Beaumont R, Crean CD, Gabig T and Freedman AS: Temporal gene
expression profile of human precursor B leukemia cells induced by
adhesion receptor: Identification of pathways regulating B-cell
survival. Blood. 101:1118–1127. 2003. View Article : Google Scholar
|
|
36
|
Walzog B and Gaehtgens P: Adhesion
molecules: The path to a new understanding of acute inflammation.
News Physiol Sci. 15:107–113. 2000.
|
|
37
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu D, Zhao B, Qi X, Peng F, Fu H, Chi X,
Miao QR and Shao S: Nogo-B receptor promotes epithelial-mesenchymal
transition in non-small cell lung cancer cells through the
Ras/ERK/Snail1 pathway. Cancer Lett. 418:135–146. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mak VC, Wong OG, Siu MK, Wong ES, Ng WY,
Wong RW, Chan KK, Ngan HY and Cheung AN: FBI-1 is overexpressed in
gestational trophoblastic disease and promotes tumor growth and
cell aggressiveness of choriocarcinoma via PI3K/Akt signaling. Am J
Pathol. 185:2038–2048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang QL, Xing XZ, Li FY, Xing YJ and Li
J: Pretreatment Pokemon level as a predictor of response to
cisplatin and Paclitaxel in Patients with Unresectable Non-Small
Cell Lung Cancer. Oncol Res Treat. 38:496–502. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim JK, Kim KD, Lee E, Lim JS, Cho HJ,
Yoon HK, Cho MY, Baek KE, Park YP, Paik SG, et al: Up-regulation of
Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human
bladder cancer cell line. Cancer Lett. 212:61–70. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang CY, Guttridge DC, Mayo MW and Baldwin
AS Jr: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1
to preferentially suppress chemotherapy-induced apoptosis. Mol Cell
Biol. 19:5923–5929. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kwon OH, Kim JH, Kim SY and Kim YS:
TWEAK/Fn14 signaling mediates gastric cancer cell resistance to
5-fluorouracil via NF-κB activation. Int J Oncol. 44:583–590. 2014.
View Article : Google Scholar
|
|
44
|
Zhao X, Ning Q, Sun X and Tian D: Pokemon
reduces Bcl-2 expression through NF-κ Bp65: A possible mechanism of
hepa-tocellular carcinoma. Asian Pac J Trop Med. 4:492–497. 2011.
View Article : Google Scholar : PubMed/NCBI
|
